|Articles|May 15, 2020

Latest in People and Business

The latest happenings in the industry, all in one place.

People News

Cytel Inc. has announced the hire of Thomas Bregenzer as the new Global Head of Biostatistics.

Datacubed Health has named Brett Kleger as its new CEO.

AiCure appoints former Medidata Founder, Dr. Ed Ikeguchi, as CEO.

Illingworth Research Group has announced that John Illingworth, the founder, owner and current Chief Executive Officer (CEO), is moving into the position of Chairman. The CEO position will be taken by the current Chief Operating Officer (COO), Helen Springford. Gerard Barron, previously Director of Clinical Operations, has been promoted to Vice President, Operations. Lastly, Director of Research Nursing, Juliet Hulse has been promoted to Senior Director Global Research Nursing Strategy and Patient Advocacy.

Business News

The Regulatory Affairs Professionals Society (RAPS) added another European chapter as it announced the launch of the RAPS Germany Chapter.

Datacubed Health announced the launch of Linkt Virtual Visit, the latest module to its patient engagement/eCOA solution.

Parexel announced the deployment of nearly 30 employee volunteers to help administer and oversee COVID-19 testing across the UK in partnership with the Association of Clinical Research Organizations.

Recognition

CluePoints announced that its recently launched complimentary COVID-19 risk assessment package and Data Surveillance solution is being utilized in over 200 ongoing studies that are directly affected by COVID-19.

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related to this article

September 30th, 2026

Where AI Leads in Trial Design—and Where Humans Still Need To

In this video interview, Claire Riches, VP of clinical solutions at Citeline, makes the case for AI as a sophisticated strategic advisor in trial design while arguing that humans must remain in the lead—especially when factors the model can't fully account for are at stake.

September 30th, 2026

ACT Brief: Enrollment Feasibility Pressure-Testing, RWE Infrastructure Gaps, and Peptide Rulemaking Standstill

In today's ACT Brief, we examine how data drives honest enrollment assumptions, why RWE infrastructure lags ambition, and the disconnect between FDA rulemaking and enforcement on compounded therapies.

© FlowStudio - © FlowStudio - stock.adobe.com

September 29th, 2026

Real-World Evidence Is Moving Upstream: Is the Data Infrastructure Ready?

RWE is finding a role earlier in drug development than ever before, but the data quality, integration, and organizational alignment required to make it regulatory-grade are still catching up to the ambition.

September 29th, 2026

The Data Inputs That Matter Most When Pressure-Testing a Protocol's Feasibility

In this video interview, Claire Riches, VP of clinical solutions at Citeline, explains why combining analog trial performance data with real-world patient data and site-level recruitment history gives sponsors a far more honest picture of whether their enrollment assumptions are actually achievable.

September 29th, 2026

ACT Brief: Trial Simulations and Protocol Risk, RBQM Financial Value Quantified, and Three Drug Approvals

In today's ACT Brief, we examine what AI simulations surface in trial design, how RBQM delivers measurable financial returns, and three new FDA-approved treatments across hair loss, movement disorder, and bone disease.

September 28th, 2026

Quantifying the Financial Value of RBQM: Q&A with Sylviane de Viron, CluePoints, and Abigail Dirks, Tufts CSDD

In this Q&A, Sylviane de Viron of CluePoints and Abigail Dirks, MS, of Tufts CSDD discuss the findings of a collaborative study quantifying the financial value of RBQM, why time savings emerged as the largest driver, and what sponsors struggling to justify adoption now have that they didn't before.

September 28th, 2026

The Design Flaws Trial Simulations Surface That Traditional Planning Misses

In this video interview, Claire Riches, VP of clinical solutions at Citeline, walks through the categories of hidden protocol risk that AI-driven simulations can identify—from overly restrictive eligibility criteria to patient dropout patterns and structural trial assumptions.

September 28th, 2026

ACT Brief: AI Expands Endpoint Options, CRO Oversight Documentation, and Kidney Cancer Approval

In today's ACT Brief, we examine how AI is surfacing endpoint options beyond traditional design thinking, why sponsor oversight of outsourced work often fails on inspection despite being robust in practice, and a new combination drug for advanced kidney cancer.